A therapeutic cancer vaccine against GL261 murine glioma

Journal of Translational Medicine

Research

Michael T. Smith¹  Hong Zhu²  Jin Yu²  Mark S. Kindy²  Sebastiano Gattoni-Celli³ 

[1] Department of Pathology & Laboratory Medicine, Medical University of South Carolina, 29425, Charleston, SC, USA;Department of Pharmaceutical Sciences, University of South Florida, 33612, Tampa, FL, USA;Department of Radiation Oncology, Medical University of South Carolina, 29425, Charleston, SC, USA;Ralph H. Johnson VA Medical Center, 29401, Charleston, SC, USA;

关键词: Glioblastoma;    Immunotherapy;    Semi-allogeneic;    Cancer;    Vaccine;   

DOI  :  10.1186/s12967-015-0757-9

 received in 2015-09-25, accepted in 2015-12-18,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundGlioblastoma (GBM) is the deadliest of brain tumors. Standard treatment for GBM is surgery, followed by combined radiation therapy and chemotherapy. Current therapy prolongs survival but does not offer a cure. We report on a novel immunotherapy against GBM, tested in an animal model of C57BL/6 mice injected intra-cranially with a lethal dose of murine GL261 glioma cells.MethodsTen week-old C57BL/6 mice were anesthetized before injection of 2 × 104 GL261 cells in the right cerebral hemisphere and after 3 days half of the mice were administered a single subcutaneous (s.c.) injection of irradiated semi-allogeneic vaccine, while mock-vaccinated mice received a s.c. injection of phosphate-buffered saline (PBS). Tumor engraftment was monitored through bioluminescence imaging (BLI). Length of animal survival was measured by Kaplan–Meier graphs and statistics. At time of sacrifice brain tissue was processed for estimation of tumor size and immunohistochemical studies.ResultsOverall survival of vaccinated mice was significantly longer compared to mock-vaccinated mice. Five to ten percent of vaccinated mice survived more than 90 days following the engraftment of GL261 cells in the brain and appeared to be free of disease by BLI. Tumor volume in the brain of vaccinated mice was on average five to ten-fold smaller compared to mock-vaccinated mice. In vaccinated mice, conspicuous microglia infiltrates were observed in tumor tissue sections and activated microglia appeared to form a fence along the perimeter of the tumor cells. The results of these animal studies persuaded the Office of Orphan Products Development of the Food and Drug Administration (FDA) to grant Orphan Drug Designation for treatment of GBM with irradiated, semi-allogeneic vaccines.ConclusionsOur preclinical observations suggest that semi-allogeneic vaccines could be tested clinically on subjects with GBM, as an adjuvant to standard treatment.

【 授权许可】

CC BY   
© Kindy et al. 2016